<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14026">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344305</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP129</org_study_id>
    <nct_id>NCT00344305</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children</brief_title>
  <official_title>A Phase 2, Open-Label, Single Arm Trial to Evaluate the Shedding and Safety of CAIV-T Administered to Children 6 to Less Than 60 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, single arm, multicenter study of the shedding and safety of a single dose of
      trivalent, influenza virus vaccine live, intranasal in children 6 to &lt; 60 months of age,
      with 28-day shedding follow-up and 180-day safety follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2, open-label, single-arm, multicenter study designed to evaluate vaccine
      virus shedding and safety of trivalent influenza virus vaccine live, intranasal in children
      6 to &lt; 60 months of age. Enrollment of approximately 200 subjects was stratified by age,
      with 100 subjects 6 to &lt; 24 months of age (who reached their sixth month but not their
      second year birthday) and 100 subjects 24 to &lt; 60 months of age (who reached their second
      year but not their fifth year birthday). Baseline medical history data collection included
      the subject's prior receipt of influenza vaccine or history of laboratory-confirmed
      influenza illness in the previous influenza season.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Subjects Who Shed Vaccine Virus (Virus in the Nose of the Recipient That Was Recovered and Cultured From Respiratory Secretions Following Vaccination)</measure>
    <time_frame>Day 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were evaluated for viral shedding (A/New Caledonia/20/99 [H1N1]; A/Wyoming/03/2003 [H3N2] (A/Fujian/411/2002-like); B/Jilin/20/2003 [B/Shanghai/361/2002-like]) by collection of nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Subjects whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Vaccine Virus Shedding</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Confirmed Vaccine A/H1N1 Virus Shedding</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Confirmed Vaccine A/H3N2 Virus Shedding</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Confirmed Vaccine B Virus Shedding</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>This was evaluated using log transformed mean tissue culture infective dose (TCID50) for each virus strain (maximum viral quantification per strain per subject) and summarized for all subjects who shed vaccine virus and by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>This was evaluated using log (TCID50) for each virus strain and summarized for all subjects who shed vaccine virus and by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of Confirmed B Shed Vaccine Virus on Any Day</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>This was evaluated using log (TCID50) for each virus strain and summarized for all subjects who shed vaccine virus and by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic and Phenotypic Stability of A/H1N1 Shed Vaccine Virus</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Laboratory phenotypic and genotypic data were summarized by treatment and age group for subjects who shed vaccine virus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic and Phenotypic Stability of A/H3N2 Shed Vaccine Virus</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Laboratory phenotypic and genotypic data were summarized by treatment and age group for subjects who shed vaccine virus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic and Phenotypic Stability of B Shed Vaccine Virus</measure>
    <time_frame>Days 1-28 after study vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Laboratory phenotypic and genotypic data were summarized by treatment and age group for subjects who shed vaccine virus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Reactogenicity Events (REs) and Adverse Events (AEs) Through 28 Days Post Vaccination</measure>
    <time_frame>Days 0-28 after vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Reactogenicity events were predifined solicited events that could potentially occure after vaccination. The REs for this study included: fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain, muscle ache, chills, decreased activity level, decreased appetite, and irritability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events and Significant New Medical Conditions Through 180 Days Post Vaccination</measure>
    <time_frame>Days 0-180 after vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting REs in Relation to Any Vaccine Virus Shedding</measure>
    <time_frame>Days 0-28 after study vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The REs for this study included: fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain, muscle ache, chills, decreased activity level, decreased appetite, and irritability.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Trivalent influenza virus vaccine live, intranasal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intranasal dose 10^7 fluorescent focus units (FFU) of trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza virus vaccine live, intranasal</intervention_name>
    <description>A single intranasal dose of trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
    <arm_group_label>Trivalent influenza virus vaccine live, intranasal</arm_group_label>
    <other_name>FluMist</other_name>
    <other_name>CAIV-T</other_name>
    <other_name>LAIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 6 months to less than 60 months of age (reached their 6th month but
             not yet reached their 5th year birthday) at the time of study vaccination

          -  Written informed consent and HIPAA authorization obtained from the subject's
             parent/legal representative

          -  Ability of the subject's parent/legal representative to understand and comply with
             the requirements of the study

          -  Subject's parent/legal representative available by telephone

          -  Ability to complete follow-up period of 180 days after study vaccination as required
             by the protocol

        Exclusion Criteria:

          -  History of hypersensitivity to any component of trivalent influenza virus vaccine
             live, intranasal, including egg or egg products, monosodium glutamate, or porcine
             gelatin

          -  History of hypersensitivity to gentamicin

          -  History of Guillain-Barré syndrome

          -  Medically diagnosed wheezing, bronchodilator use, or steroid use (systemic or
             inhaled), by parent/legal representative report or chart review, within the 42 days
             prior to study vaccination (i.e., children with recent persistent asthma were
             excluded); or history of severe persistent asthma according to the criteria described
             in the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report

          -  Acute febrile (≥100.0°F oral or equivalent) and/or clinically significant respiratory
             illness (e.g., cough or sore throat) within 72 hours prior to study vaccination

          -  Any known immunosuppressive condition or immune deficiency disease (including HIV
             infection), or ongoing receipt of any immunosuppressive therapy

          -  Household contact who was immunocompromised (subjects were also to avoid close
             contact with immunocompromised individuals for at least 21 days after study
             vaccination)

          -  Use of aspirin or aspirin-containing products within the 30 days prior to study
             vaccination, or expected receipt through 180 days after study vaccination

          -  Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir,
             and zanamivir) within the 14 days prior to study vaccination, or expected receipt
             through 28 days after study vaccination

          -  Use of any intranasal medication within the 14 days prior to study vaccination, or
             expected receipt through 28 days after study vaccination

          -  Administration of any live virus vaccine within the 30 days prior to study
             vaccination, or expected receipt through 30 days after study vaccination

          -  Administration of any inactivated (i.e., non-live) vaccine within the 14 days prior
             to study vaccination, or expected receipt through 14 days after study vaccination

          -  Receipt of any investigational agent within the 30 days prior to study vaccination,
             or expected receipt through 180 days after study vaccination (use of licensed agents
             for indications not listed in the package insert was permitted)

          -  Receipt of any blood product within the 90 days prior to study vaccination, or
             expected receipt through 28 days after study vaccination

          -  Family member or household contact who was an employee of the research center or
             otherwise involved with the conduct of the study

          -  Any condition that in the opinion of the investigator would have interfered with
             evaluation of the vaccine or interpretation of study results
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raburn Mallory, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Little Rock Allergy &amp; Asthma Clinic, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric and Adolescent Medicine, PA (PAMPA)</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatrics/Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metarie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Research Center</name>
      <address>
        <city>Courtland</city>
        <state>New York</state>
        <zip>13045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Research Center</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Prairie Pediatrics &amp; Allergy Clinic</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research , Inc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med-Pro Research Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wee Care Pediatrics</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Pediatrics</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI-Coor Clinical Research, LLC</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pediatrics</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mallory RM, Yi T, Ambrose CS. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. Vaccine. 2011 Jun 10;29(26):4322-7. doi: 10.1016/j.vaccine.2011.04.022. Epub 2011 Apr 20.</citation>
    <PMID>21513761</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 5, 2012</lastchanged_date>
  <firstreceived_date>June 22, 2006</firstreceived_date>
  <firstreceived_results_date>July 29, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>children, FluMist, shedding,</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
          <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
        </group>
        <group group_id="P2">
          <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
          <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject was not contacted in window</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
          <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
        </group>
        <group group_id="B2">
          <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
          <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="100"/>
                <measurement group_id="B2" value="100"/>
                <measurement group_id="B3" value="200"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14.87" spread="5.50"/>
                <measurement group_id="B2" value="41.31" spread="9.98"/>
                <measurement group_id="B3" value="28.09" spread="15.50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="104"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="49"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="96"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participant</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="93"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="178"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="86"/>
                <measurement group_id="B2" value="89"/>
                <measurement group_id="B3" value="175"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="100"/>
                <measurement group_id="B2" value="100"/>
                <measurement group_id="B3" value="200"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>History of laboratory-confirmed influenza illness in previous influenza season</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Yes</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="99"/>
                <measurement group_id="B2" value="98"/>
                <measurement group_id="B3" value="197"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>History of receiving an influenza vaccine</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Yes</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="73"/>
                <measurement group_id="B3" value="116"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="84"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Shed Vaccine Virus (Virus in the Nose of the Recipient That Was Recovered and Cultured From Respiratory Secretions Following Vaccination)</title>
        <description>Subjects were evaluated for viral shedding (A/New Caledonia/20/99 [H1N1]; A/Wyoming/03/2003 [H3N2] (A/Fujian/411/2002-like); B/Jilin/20/2003 [B/Shanghai/361/2002-like]) by collection of nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Subjects whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.</description>
        <time_frame>Day 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Shedding population. One subject was excluded because of receipt of HBV vaccination 3 days prior to study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Shed Vaccine Virus (Virus in the Nose of the Recipient That Was Recovered and Cultured From Respiratory Secretions Following Vaccination)</title>
            <description>Subjects were evaluated for viral shedding (A/New Caledonia/20/99 [H1N1]; A/Wyoming/03/2003 [H3N2] (A/Fujian/411/2002-like); B/Jilin/20/2003 [B/Shanghai/361/2002-like]) by collection of nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Subjects whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/H1N1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/H3N2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Any Vaccine Virus Shedding</title>
        <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Shedding population of subjects who actually shed any vaccine virus. In addition, one subject was excluded because of receipt of HBV vaccination 3 days prior to study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Any Vaccine Virus Shedding</title>
            <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
            <units>Number of days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" spread="1.5"/>
                  <measurement group_id="O2" value="2.7" spread="1.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Confirmed Vaccine A/H1N1 Virus Shedding</title>
        <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Shedding population of subjects who actually shed a confirmed strain. In addition, one subject was excluded because of receipt of HBV vaccination 3 days prior to study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Confirmed Vaccine A/H1N1 Virus Shedding</title>
            <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
            <units>Number of days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" spread="1.0"/>
                  <measurement group_id="O2" value="2.2" spread="1.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Confirmed Vaccine A/H3N2 Virus Shedding</title>
        <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Shedding population of subjects who actually shed a confirmed strain. In addition, one subject was excluded because of receipt of HBV vaccination 3 days prior to study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Confirmed Vaccine A/H3N2 Virus Shedding</title>
            <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
            <units>Number of days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.8" spread="0.9"/>
                  <measurement group_id="O2" value="1.7" spread="0.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Confirmed Vaccine B Virus Shedding</title>
        <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Shedding population of subjects who actually shed a confirmed strain. In addition, one subject was excluded because of receipt of HBV vaccination 3 days prior to study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Confirmed Vaccine B Virus Shedding</title>
            <description>The number of days of shedding was summarized for all subjects who shed vaccine virus and by age group.</description>
            <units>Number of days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" spread="1.5"/>
                  <measurement group_id="O2" value="1.8" spread="1.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day</title>
        <description>This was evaluated using log transformed mean tissue culture infective dose (TCID50) for each virus strain (maximum viral quantification per strain per subject) and summarized for all subjects who shed vaccine virus and by age group.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Shedding population of subjects who actually shed a confirmed strain. In addition, one subject was excluded because of receipt of HBV vaccination 3 days prior to study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Quantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day</title>
            <description>This was evaluated using log transformed mean tissue culture infective dose (TCID50) for each virus strain (maximum viral quantification per strain per subject) and summarized for all subjects who shed vaccine virus and by age group.</description>
            <units>log (TCID50) per mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.14" spread="0.98"/>
                  <measurement group_id="O2" value="2.62" spread="0.97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day</title>
        <description>This was evaluated using log (TCID50) for each virus strain and summarized for all subjects who shed vaccine virus and by age group.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Shedding population of subjects who actually shed a confirmed strain. In addition, one subject was excluded because of receipt of HBV vaccination 3 days prior to study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Quantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day</title>
            <description>This was evaluated using log (TCID50) for each virus strain and summarized for all subjects who shed vaccine virus and by age group.</description>
            <units>log (TCID50) per mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.59" spread="0.95"/>
                  <measurement group_id="O2" value="1.10" spread="0.53"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitation of Confirmed B Shed Vaccine Virus on Any Day</title>
        <description>This was evaluated using log (TCID50) for each virus strain and summarized for all subjects who shed vaccine virus and by age group.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Shedding population of subjects who actually shed a confirmed strain. In addition, one subject was excluded because of receipt of HBV vaccination 3 days prior to study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Quantitation of Confirmed B Shed Vaccine Virus on Any Day</title>
            <description>This was evaluated using log (TCID50) for each virus strain and summarized for all subjects who shed vaccine virus and by age group.</description>
            <units>log (TCID50) per mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.70" spread="1.09"/>
                  <measurement group_id="O2" value="1.24" spread="0.68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genotypic and Phenotypic Stability of A/H1N1 Shed Vaccine Virus</title>
        <description>Laboratory phenotypic and genotypic data were summarized by treatment and age group for subjects who shed vaccine virus.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The shedding population included subjects who received a full dose of investigational product and who had valid assay results from nasal specimens obtained at any post-dosing time point were evaluable for shedding.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of samples analyzed</title>
            <units>samples</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Genotypic and Phenotypic Stability of A/H1N1 Shed Vaccine Virus</title>
            <description>Laboratory phenotypic and genotypic data were summarized by treatment and age group for subjects who shed vaccine virus.</description>
            <units>samples</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>genotypiclly and phenotypically stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>genotypically and phenotypically unstable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genotypic and Phenotypic Stability of A/H3N2 Shed Vaccine Virus</title>
        <description>Laboratory phenotypic and genotypic data were summarized by treatment and age group for subjects who shed vaccine virus.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The shedding population included subjects who received a full dose of investigational product and who had valid assay results from nasal specimens obtained at any post-dosing time point were evaluable for shedding.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of samples analyzed</title>
            <units>samples</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Genotypic and Phenotypic Stability of A/H3N2 Shed Vaccine Virus</title>
            <description>Laboratory phenotypic and genotypic data were summarized by treatment and age group for subjects who shed vaccine virus.</description>
            <units>samples</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>genotypically and phenotypically stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>genotypically and phenotypically unstable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genotypic and Phenotypic Stability of B Shed Vaccine Virus</title>
        <description>Laboratory phenotypic and genotypic data were summarized by treatment and age group for subjects who shed vaccine virus.</description>
        <time_frame>Days 1-28 after study vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The shedding population included subjects who received a full dose of investigational product and who had valid assay results from nasal specimens obtained at any post-dosing time point were evaluable for shedding.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of samples analyzed</title>
            <units>samples</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Genotypic and Phenotypic Stability of B Shed Vaccine Virus</title>
            <description>Laboratory phenotypic and genotypic data were summarized by treatment and age group for subjects who shed vaccine virus.</description>
            <units>samples</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>genotypically and phenotypically stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>genotypically and phenotypically unstable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Reactogenicity Events (REs) and Adverse Events (AEs) Through 28 Days Post Vaccination</title>
        <description>Reactogenicity events were predifined solicited events that could potentially occure after vaccination. The REs for this study included: fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain, muscle ache, chills, decreased activity level, decreased appetite, and irritability.</description>
        <time_frame>Days 0-28 after vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Reactogenicity Events (REs) and Adverse Events (AEs) Through 28 Days Post Vaccination</title>
            <description>Reactogenicity events were predifined solicited events that could potentially occure after vaccination. The REs for this study included: fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain, muscle ache, chills, decreased activity level, decreased appetite, and irritability.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any RE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with at least 1 AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events and Significant New Medical Conditions Through 180 Days Post Vaccination</title>
        <time_frame>Days 0-180 after vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events and Significant New Medical Conditions Through 180 Days Post Vaccination</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Serious adverse events</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Significant new medical conditions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting REs in Relation to Any Vaccine Virus Shedding</title>
        <description>The REs for this study included: fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain, muscle ache, chills, decreased activity level, decreased appetite, and irritability.</description>
        <time_frame>Days 0-28 after study vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Subjects who had REs and were in the shedding population.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
            <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting REs in Relation to Any Vaccine Virus Shedding</title>
            <description>The REs for this study included: fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain, muscle ache, chills, decreased activity level, decreased appetite, and irritability.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs Days 0-28 post dosing SAE Days 0-180 post dosing</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Trivalent Influenza Virus Vaccine 6 to &lt; 24 Months</title>
          <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
        </group>
        <group group_id="E2">
          <title>Trivalent Influenza Virus Vaccine 24 to &lt; 60 Months</title>
          <description>A single intranasal dose of 10^7 FFU trivalent influenza virus vaccine live, intranasal was administered on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>OTORRHOEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>TEETHING</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HERPANGINA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ARTHROPOD STING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BODY TEMPERATURE INCREASED</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>HEAT RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restricion is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raburn Mallory MD/ Sr Dir Clinical Development</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>301-398-0000</phone>
      <email>clinicaltrialenquiries@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
